Posted on 09/08/2010 in Pharmaceutical Company Financials Pfizer has published its financial report for the second quarter of the 2010 fiscal year, which reflects its business growth following the merger with Wyeth.
The company's revenue figure for the quarter came to $17.3 billion (10.8 billion pounds), a year-on-year increase of 58 per cent, with legacy Wyeth products accounting for $5.4 billion of this total.
Pfizer attributed much of its second quarter success to sales of Prevnar/Prevenar 13, as well as several key products from its primary care, specialty care and oncology portfolios.
In the coming months, it will launch its new emerging markets business unit, as well as publishing new clinical trial data for treatments such as Prevnar 13, Sutent and tasocitinib.
Jeff Kindler, chairman and chief executive officer of Pfizer, said: "Pfizer's more balanced global portfolio, which includes small molecules, biologics and vaccines as well as off-patent pharmaceuticals and diversified products, generated strong performance in a period of notable worldwide economic uncertainty."
Last month, Pfizer announced a new collaboration with Samsung Medical Center to develop a range of liver cancer therapies. Other news stories from 09/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
